AgomAb shares surge 53.56% after-hours as IPO closes, raising $200M on Nasdaq.

AgomAb Therapeutics NV (Nasdaq: AGMB) surged 53.56% in after-hours trading following the announcement of its successful initial public offering. The company closed its IPO on February 6, 2026, issuing 12.5 million American Depositary Shares at $16.00 each, generating approximately $200 million in gross proceeds. The offering, managed by J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen, marked AgomAb’s debut on the Nasdaq Global Select Market. The significant capital raise and market entry likely fueled investor optimism about the clinical-stage biopharmaceutical firm’s focus on developing therapies for chronic fibrotic diseases, positioning it to advance its pipeline and address high-unmet medical needs. The after-hours rally reflects strong market confidence in the company’s growth potential post-IPO.